BDSI

Read more
Jeffrey A. Bailey's photo - CEO of BDSI

CEO

Jeffrey A. Bailey

CEO Approval Rating

89/100

Founded:

1997

Status:

PublicIndependent CompanyNASDAQBDSI

BDSI TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

BDSI's company profile
Jeffrey A. Bailey's photo - CEO of BDSI

Jeffrey A. Bailey

CEO

89/100
164
$206.2M
$164.1M
View Profile
1
BDSI's Competitor - Collegium Pharmaceutical logo
Joseph Ciaffoni's photo - CEO of Collegium Pharmaceutical

Joseph Ciaffoni

CEO

85/100
266
$447.1M
$326.1M
View Profile
2
BDSI's Competitor - Zyla Life Sciences logo
Todd Smith's photo - President & CEO of Zyla Life Sciences

Todd Smith

President & CEO

88/100
154
$234.5M
$30.4M
View Profile
3
BDSI's Competitor - Flexion Therapeutics logo
Mike Clayman's photo - Co-Founder & CEO of Flexion Therapeutics

Mike Clayman

Co-Founder & CEO

74/100
272
$190M
$102.7M
View Profile
4
BDSI's Competitor - Zogenix logo
Stephen J. Farr's photo - President & CEO of Zogenix

Stephen J. Farr

President & CEO

81/100
90
$494.3M
$43.8M
View Profile
5
BDSI's Competitor - Ethypharm logo
Bertrand Deluard's photo - CEO of Ethypharm

Bertrand Deluard

CEO

81/100
950
- -
$15M
View Profile
6
BDSI's Competitor - Calmare logo
Conrad F Mir's photo - President & CEO of Calmare

Conrad F Mir

President & CEO

78/100
7
$550.1K
$ < 1M
View Profile
7
BDSI's Competitor - Spinifex Pharmaceuticals Pty. Ltd. logo
Tom McCarthy's photo - President & CEO of Spinifex Pharmaceuticals Pty. Ltd.

Tom McCarthy

President & CEO

66/100
30
$66.5M
View Profile
8
BDSI's Competitor - Calmar Pain Relief logo
Stephen J. D’Amato's photo - Founder of Calmar Pain Relief

Stephen J. D’Amato

Founder

68/100
20
- -
$4.4M
View Profile
9
BDSI's Competitor - Endo logo
Blaise Coleman's photo - President & CEO of Endo

Blaise Coleman

President & CEO

88/100
3,397
$2.8B
$2.8B
View Profile
10
BDSI's Competitor - XenoPort logo
Vincent J. Angotti's photo - CEO of XenoPort

Vincent J. Angotti

CEO

69/100
600
$72.5M
$48.2M
View Profile
11
BDSI's Competitor - Grunenthal logo
Gabriel Baertschi's photo - Chairman & CEO of Grunenthal

Gabriel Baertschi

Chairman & CEO

76/100
4,500
- -
$1.6B
View Profile
12
BDSI's Competitor - Thesan Pharmaceuticals, Inc. logo
CEO Avatar

Bernard D. King

CEO

86/100
6
$65M
$4M
View Profile

Missing a competitor? Contribute!

Collegium Pharmaceutical is seen as one of BDSI's biggest rivals. Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts, and was founded in 2003. Like BDSI, Collegium Pharmaceutical also works within the Pharmaceuticals sector. Collegium Pharmaceutical generates 198% the revenue of BDSI.

Zyla Life Sciences is seen as one of BDSI's top competitors. Zyla Life Sciences was founded in 1995, and its headquarters is in Wayne, Pennsylvania. Zyla Life Sciences operates in the Pharmaceuticals industry. Zyla Life Sciences has 37 fewer employees than BDSI.

Flexion Therapeutics is one of BDSI's top rivals. Flexion Therapeutics is a Public company that was founded in Burlington, Massachusetts in 2007. Flexion Therapeutics operates in the Pharmaceuticals industry. Flexion Therapeutics has 93 more employees vs. BDSI.

BDSI Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$164.1M

BDSI's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 450.7M. Over the last four quarters, BDSI's revenue has grown by 5.1%. Specifically, in Q2 2021's revenue was $41.4M; in Q1 2021, it was $41M; in Q4 2020, it was $42.2M; in Q3 2020, BDSI's revenue was $39.4M.

BDSI Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION

-

Arius Pharmaceuticals

Aug 2004

Source »
$7M
-

These are all the companies that BDSI has acquired. BDSI's latest acquisition was Arius Pharmaceuticals in Aug 2004.

BDSI Funding History

Since BDSI was founded in 1997, it has participated in 8 rounds of funding. In total BDSI has raised $206.2M. BDSI's last funding round was on May 2018 for a total of $50.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Equity
May 2018
$50M
Post-IPO Debt
Feb 2017
$45M
Post-IPO Debt
May 2015
$20.7M
-
Post-IPO Equity
Feb 2014
$60M
-
Post-IPO Debt
Jul 2013
$20M
-

Since BDSI was founded in 1997, it has participated in 8 rounds of funding. In total BDSI has raised $206.2M. BDSI's last funding round was on May 2018 for a total of $50.0M

BDSI Investments

No recent investments found related to BDSI

BDSI News

September 7, 2021Benzinga

BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA to Oxycodone at the PAINWeek 2021 Conference

RALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BD... See more »
August 5, 2021India Infoline

Dr Reddy's Lab signs deal with BioDelivery Sciences to sell US and Canada territory rights for EL YXYB

As per the agreement, Dr Reddy's will receive $6 million upfront upon closing followed by $9 million ... See more »
August 4, 2021MarketScreener

Press Release (Form 6-K)

(marketscreener.com) Sub: Press Release Please find enclosed a Press Release on 'Dr. Reddy's Laborato... See more »
August 4, 2021WRAL TechWire

Raleigh pharma firm BDSI paying millions to acquire migraine treatment

BioDelivery Sciences International is paying millions to acquire rights in the U.S. and Canada for an... See more »
August 4, 2021Benzinga

BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range

BioDelivery Sciences International Inc (NASDAQ: BDSI) has reported Q2 sales of $41.4 million, + 13.3%... See more »
April 20, 2021BioSpace

BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical c... See more »

BDSI Press Releases

April 28, 2020GlobeNewswire

BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020

RALEIGH, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: B... See more »
December 19, 2019GlobeNewswire

BioDelivery Sciences Added to NASDAQ Biotechnology Index

RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BD... See more »
December 11, 2019StreetInsider

Emmy® and Tony Award® Winning Actress Kristin Chenoweth Introduces 'This Is Pain' Campaign to Improve the Lives of Those Living with Chronic Pain

RALEIGH, N.C., Dec. 11, 2019 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI),... See more »
November 12, 2019GlobeNewswire

BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations

BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million... See more »
October 1, 2019GlobeNewswire

BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated... See more »
June 24, 2019GlobeNewswire

BioDelivery Sciences Expands Upon Report from Pain Management Task Force

Company's Activities Support Buprenorphine Recommendations Including:... See more »
May 29, 2019GlobeNewswire

BioDelivery Sciences Announces Upcoming Investor Conference Presentations

RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDS... See more »

Social Media

BDSI Headquarters

4131 Parklake Avenue Suite 225

Raleigh, North Carolina27612

919-582-9050

Driving Directions »

Trending Companies

BDSI Summary

ABOUT

Overview

BDSI is a biotechnology company that researches and commercializes proprietary drugs for the treatment of pain management and addiction. BDSI was founded in 1997. BDSI's headquarters is located in Raleigh, North Carolina, USA 27612. It has raised 206....

CEO

BDSI's CEO, Jeffrey A. Bailey, currently has an approval rating of 89%. BDSI's primary competitors are Collegium Pharmaceutical, Zyla Life Sciences & Flexion Therapeutics.

Website

bdsi.com

Frequently Asked Questions about BDSI

  1. When was BDSI founded?

    BDSI was founded in 1997
  2. Who is BDSI's CEO?

    BDSI's CEO is Jeffrey A. Bailey
  3. How much revenue does BDSI generate?

    BDSI generates $164.1M in revenue
  4. How much funding does BDSI have?

    BDSI has historically raised $206.2M in funding
  1. Where is BDSI's headquarters?

    BDSI's headquarters is in Raleigh North Carolina, USA
  2. How many employees does BDSI have?

    BDSI has 164 employees
  3. What sector does BDSI operate in?

    BDSI is in Pharmaceuticals
  4. Who are BDSI's competitors?

    BDSI's top competitors are Collegium Pharmaceutical, Zyla Life Sciences, Flexion Therapeutics